促红细胞生成素在创伤性脑损伤合并颅外损伤患者中的应用——EPO-TBI试验的事后分析
该研究为EPO-TBI随机对照试验的事后分析,纳入2009至2014年603例TBI患者,计算排除头面部成分的颅外损伤严重度评分(ISS),并将多发性创伤定义为至少两个体区AIS评分≥3分。采用Cox回归分析EPO对死亡时间的影响,结果显示EPO与较高颅外ISS患者的死亡率降低相关(交互作用P=0.048),与多发性创伤的交互作用较弱(P=0.17)。在颅外ISS>6的患者中,6个月时EPO组147例中10例(6.8%)死亡,安慰剂组154例中26例(17%)死亡,风险降低10%(95%CI 2.9-17%,P=0.007)。作者认为EPO可能对颅外损伤较重的TBI患者有差异化的6个月死亡率改善作用,但需未来临床和实验研究确认。
要点
- 在颅外ISS>6的TBI患者中,6个月时EPO组死亡10/147(6.8%),安慰剂组死亡26/154(17%),风险降低10%(95%CI 2.9-17%,P=0.007)。
- Cox回归显示EPO与较高颅外ISS患者的死亡率降低相关(交互作用P=0.048)。
- 多发性创伤(至少两个体区AIS评分≥3分)与EPO的交互作用较弱(P=0.17)。
- 纳入603例患者,颅外ISS中位数6(四分位距1-13),258例(43%)至少两个体区AIS评分≥3分。
- 作者结论认为EPO可能对颅外损伤较重的TBI患者有差异化的6个月死亡率改善作用,需未来临床和实验研究确认。
适用人群与场景
- EPO-TBI随机对照试验纳入的创伤性脑损伤患者,共603例,来自2009至2014年。
- 多发性创伤定义为至少两个体区AIS评分≥3分,共258例(43%)。
诊断标准与关键阈值
- 颅外损伤严重度评分(ISS)包括ISS的相同组成部分,但排除头面部成分,中位数为6(四分位距1-13)。
- 多发性创伤定义为两个受损体区AIS评分≥3分。
研究设计与关键结果
- 研究类型:EPO-TBI随机对照试验的事后分析,纳入603例患者。
- 主要分析:Cox回归显示EPO与较高颅外ISS患者的死亡率降低相关(交互作用P=0.048),与多发性创伤的交互作用较弱(P=0.17)。
- 6个月死亡率:在颅外ISS>6的患者中,EPO组147例中10例(6.8%)死亡,安慰剂组154例中26例(17%)死亡,风险降低10%(95%CI 2.9-17%,P=0.007)。
证据类型、等级与局限
- 证据类型:随机对照试验的事后分析。
- 证据等级:治疗性研究,III级。
- 局限:作者结论指出这些发现需未来临床和实验研究确认。
对床旁实践的改变
- 作者认为EPO可能对颅外损伤较重的TBI患者有差异化的6个月死亡率改善作用,但需未来临床和实验研究确认。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Erythropoietin (EPO) may reduce mortality after traumatic brain injury (TBI). Secondary brain injury is exacerbated by multiple trauma, and possibly modifiable by EPO. We hypothesized that EPO decreases mortality more in TBI patients with multiple trauma, than in patients with TBI alone.
METHODS: A post hoc analysis of the EPO-TBI randomized controlled trial conducted in 2009 to 2014. To evaluate the impact of injuries outside the brain, we calculated an extracranial Injury Severity Score (ISS) that included the same components of the ISS, excluding head and face components. We defined multiple trauma as two injured body regions with an Abbreviated Injury Scale (AIS) score of 3 or higher. Cox regression analyses, allowing for potential differential responses per the presence or absence of extracranial injury defined by these injury scores, were used to assess the effect of EPO on time to mortality.
RESULTS: Of 603 included patients, the median extracranial ISS was 6 (interquartile range, 1-13) and 258 (43%) had an AIS score of 3 or higher in at least two body regions. On Cox regression, EPO was associated with decreased mortality in patients with greater extracranial ISS (interaction p = 0.048) and weakly associated with differential mortality with multiple trauma (AIS score > 3 or in two regions, interaction p = 0.17). At 6 months in patients with extracranial ISS higher than 6, 10 (6.8%) of 147 EPO-treated patients compared with 26 (17%) of 154 placebo-treated patients died (risk reduction, 10%; 95% confidence interval, 2.9-17%; p = 0.007).
CONCLUSION: In this post hoc analysis, EPO administration was associated with a potential differential improvement in 6-month mortality in TBI patients with more severe extracranial injury. These findings need confirmation in future clinical and experimental studies.
LEVEL OF EVIDENCE: Therapeutic study, level III.
参考来源
- Skrifvars MB, Bailey M, French C, et al. Erythropoietin in patients with traumatic brain injury and extracranial injury-A post hoc analysis of the erythropoietin traumatic brain injury trial. J Trauma Acute Care Surg. 2017. PMID: 28590358. doi:10.1097/TA.0000000000001594
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。